Time from the end of induction with EEN to the start of anti-TNF
4.5
$ 10.99
In stock
(491)
Product Description
Anti-TNF therapeutics for the treatment of sarcoidosis
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
IJMS, Free Full-Text
TNF alpha Monoclonal Antibody (MAb11), Biotin (13-7349-81)
Frontiers Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
Frontiers Macrophages: The Good, the Bad, and the Gluttony
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial - The Lancet Gastroenterology & Hepatology
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial - The Lancet
Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease
Switching Between Biologics in Inflammatory Bowel Disease
TNF alpha Monoclonal Antibody (MP6-XT22) (14-7321-81)
